153 related articles for article (PubMed ID: 38396898)
1. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.
Paniagua-Herranz L; Moreno I; Nieto-Jiménez C; Garcia-Lorenzo E; Díaz-Tejeiro C; Sanvicente A; Doger B; Pedregal M; Ramón J; Bartolomé J; Manzano A; Gyorffy B; Gutierrez-Uzquiza Á; Pérez Segura P; Calvo E; Moreno V; Ocana A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396898
[TBL] [Abstract][Full Text] [Related]
2. Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract][Full Text] [Related]
3. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
4. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.
Lee JK; Bangayan NJ; Chai T; Smith BA; Pariva TE; Yun S; Vashisht A; Zhang Q; Park JW; Corey E; Huang J; Graeber TG; Wohlschlegel J; Witte ON
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4473-E4482. PubMed ID: 29686080
[TBL] [Abstract][Full Text] [Related]
5. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
[TBL] [Abstract][Full Text] [Related]
6. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
7. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
Williams SA; Xu Y; De Marzo AM; Isaacs JT; Denmeade SR
Prostate; 2010 May; 70(7):788-96. PubMed ID: 20058238
[TBL] [Abstract][Full Text] [Related]
9. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
11. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
12. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.
Avgeris M; Stravodimos K; Scorilas A
Biol Chem; 2014 Sep; 395(9):1095-104. PubMed ID: 25153390
[TBL] [Abstract][Full Text] [Related]
13. Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2.
Cheng J; Zhou J; Fu S; Fu J; Zhou B; Chen H; Fu J; Wei C
J Cell Mol Med; 2021 Apr; 25(8):4157-4165. PubMed ID: 33609069
[TBL] [Abstract][Full Text] [Related]
14. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
15. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Liao J; Ye Y; Xu X
Clin Transl Oncol; 2022 Oct; 24(10):1986-1997. PubMed ID: 35732871
[TBL] [Abstract][Full Text] [Related]
17. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract][Full Text] [Related]
18. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.
Liang L; Shang J; Zhang Y; Xu Y; Zhouteng Y; Wen J; Zhao Y; Feng N; Zhao R
Aging (Albany NY); 2023 Oct; 15(19):10168-10192. PubMed ID: 37788005
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Yousef GM; Scorilas A; Chang A; Rendl L; Diamandis M; Jung K; Diamandis EP
Prostate; 2002 May; 51(2):126-32. PubMed ID: 11948967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]